You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR TRASTUZUMAB


✉ Email this page to a colleague

« Back to Dashboard


Biosimilar Clinical Trials for trastuzumab

This table shows clinical trials for biosimilars. See the next table for all clinical trials
Trial ID Title Status Sponsor Phase Start Date Summary
NCT01439191 ↗ Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer Completed Shanghai CP Guojian Pharmaceutical Co., Ltd. Phase 2 2005-07-01 The HER2 gene (also known as HER2/neu and ErbB2 gene) is overexpressed in 20-30% of human breast cancers and leads to a particularly aggressive form of the disease. Trastuzumab,a humanized anti-HER2/neu receptor monoclonal antibody, has been proved a valuable treatment for HER2-positive breast cancer patients.The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone. CMAB302, a biosimilar of trastuzumab, was developed by Shanghai CP Guojian Pharmaceutical Co.Ltd. Efficacy and safety of CMAB302 as a single agent or in combination with vinorelbine were evaluated in patients with HER2-overexpressing metastatic breast cancer.
NCT01439191 ↗ Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer Completed Shanghai CP Guojian Pharmaceutical Co.,Ltd. Phase 2 2005-07-01 The HER2 gene (also known as HER2/neu and ErbB2 gene) is overexpressed in 20-30% of human breast cancers and leads to a particularly aggressive form of the disease. Trastuzumab,a humanized anti-HER2/neu receptor monoclonal antibody, has been proved a valuable treatment for HER2-positive breast cancer patients.The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone. CMAB302, a biosimilar of trastuzumab, was developed by Shanghai CP Guojian Pharmaceutical Co.Ltd. Efficacy and safety of CMAB302 as a single agent or in combination with vinorelbine were evaluated in patients with HER2-overexpressing metastatic breast cancer.
NCT02149524 ↗ A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer Completed Samsung Bioepis Co., Ltd. Phase 3 2014-04-01 A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting
NCT03013504 ↗ A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients Active, not recruiting Prestige Biopharma Limited Phase 3 2018-01-01 In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.
>Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for trastuzumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003440 ↗ Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic Completed National Cancer Institute (NCI) Phase 3 1998-07-01 This randomized phase III studies how well two different regimens of paclitaxel with or without trastuzumab works in treating patients with or without HER-2/Neu breast cancer that is inoperable, recurrent, or metastatic. Drugs used in chemotherapy, such as paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known what regimen of paclitaxel is more effective with or without trastuzumab in treating patients with breast cancer.
NCT00003539 ↗ Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus monoclonal antibody therapy in treating women with recurrent or metastatic breast cancer.
NCT00003539 ↗ Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus monoclonal antibody therapy in treating women with recurrent or metastatic breast cancer.
NCT00003612 ↗ Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 1999-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, carboplatin, and trastuzumab in treating women who have metastatic breast cancer that overexpresses HER2.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for trastuzumab

Condition Name

Condition Name for trastuzumab
Intervention Trials
Breast Cancer 458
Metastatic Breast Cancer 114
HER2-positive Breast Cancer 102
Breast Neoplasms 60
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for trastuzumab
Intervention Trials
Breast Neoplasms 851
Stomach Neoplasms 84
Neoplasm Metastasis 59
Adenocarcinoma 54
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for trastuzumab

Trials by Country

Trials by Country for trastuzumab
Location Trials
Italy 498
Spain 452
India 87
Poland 84
Mexico 79
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for trastuzumab
Location Trials
California 198
New York 186
Texas 180
Florida 169
Massachusetts 145
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for trastuzumab

Clinical Trial Phase

Clinical Trial Phase for trastuzumab
Clinical Trial Phase Trials
Phase 4 14
Phase 3 200
Phase 2/Phase 3 17
[disabled in preview] 571
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for trastuzumab
Clinical Trial Phase Trials
Completed 429
Recruiting 209
Not yet recruiting 139
[disabled in preview] 124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for trastuzumab

Sponsor Name

Sponsor Name for trastuzumab
Sponsor Trials
National Cancer Institute (NCI) 130
Hoffmann-La Roche 122
Genentech, Inc. 78
[disabled in preview] 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for trastuzumab
Sponsor Trials
Other 1079
Industry 836
NIH 132
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.